BNR

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.

Wall Street analysts forecast BNR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Burning Rock Biotech Ltd revenue for the last quarter amounts to 131.62M USD, increased 2.31 % YoY.

Burning Rock Biotech Ltd. EPS for the last quarter amounts to -0.16 USD, decreased -54.29 % YoY.

Burning Rock Biotech Ltd (BNR) has 674 emplpoyees as of December 16 2025.

Today BNR has the market capitalization of 169.68M USD.